Drugs / HER2(EQ)BBζ/CD19t+ T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03389230 | Aug 2018 → Dec 2026 expected | glioblastoma, grade III glioma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2(EQ)BBζ/CD19t+ T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03389230 ↗ |
| Action | Deplete | “Immune cells can be engineered to kill glioma cells in the laboratory” NCT03389230 ↗ |
| Modality | Cell therapy | “cellular immunotherapy utilizing ex vivo expanded autologous memory-enriched T cells” NCT03389230 ↗ |
| Route | Other | “via intratumoral/intracavitary catheter and intraventricular catheter” NCT03389230 ↗ |